Author Archives: Jan Paschal

Lyntris (LYNX) slashed its IPO’s size at pricing to 17 million shares – DOWN from 24 million shares in the prospectus – and priced the deal at $17.50 – $1.50 below the bottom of the $19.00-to-$22.00 range in the prospectus – to raise $297.5 million on Tuesday night, Aug. 18, 2026. Those numbers represent a […]

Trive Capital-backed Lyntris (LYNX Proposed) – a defense tech start-up – is the only IPO set for lift-off for the week of Aug. 17, 2026. That’s not unusual for mid-August. It’s traditionally a slow period for the IPO market – peak vacation time for many IPO pros and traders in the countdown to the Labor […]

Londian Wason New Energy Tech (FOIL) upsized its IPO at pricing to 4.3 million American Depositary Shares (ADS) – up from 3.57 million in the prospectus – and priced its IPO at $22.00 – the top of its range – to raise $94.3 million on Tuesday night, Aug. 11, 2026. The Chinese company is one […]

Lyntris Inc. (LYNX), a U.S. Department of Defense contractor, launched its $492 million IPO early today to price next week. Lyntris Inc.’s IPO consists of 24 million shares at a price range of $19.00 to $22.00 to raise $492 million – if priced at the  $20.50 mid-point  of its range, according to its S-1/A filing […]

Londian Wason New Energy Tech (FOIL Proposed) of China is the only IPO set to price in the second week of August. This shows that IPO bankers are ready for the late summer slowdown, which traditionally runs from mid-August until after Labor Day. Londian Wason, one of the world’s largest producers of copper foil for lithium […]

Upsized is the biotech word of the week. BlossomHill Therapeutics (BLSM) and Latigo Biotherapeutics (LTGO) increased the size of their IPOs at pricing and raised a total of $495.6 million on Thursday night (Aug. 6, 2026). The upsized trend held for all four biotech IPOs priced this week, including Attovia Therapeutics (ATTO) and Braveheart Bio (BRVE). Altogether, these […]

Braveheart Bio (BRVE) of San Francisco upsized its IPO at pricing and priced the deal at $18.00 – $1.00 above the top of its range – to raise $382.5 million on Wednesday night, Aug. 5, 2026. The Phase 3 biotech’s deal was increased at pricing to 21.25 million shares – up 2.5 million shares – from […]

Attovia Therapeutics (ATTO), a Phase 1 biotech developing drugs to treat chronic itching and IBD, priced its IPO at $17.00 – the top of its range, as expected – and sold 17 million shares – matching the IPO’s upsized terms disclosed this morning – to raise $289 million on Tuesday night, Aug. 4, 2026. At pricing, […]

It’s a supersized Tuesday:   Attovia Therapeutics (ATTO Proposed), a Phase 1 biotech developing drugs to treat chronic pruritis (itching) and IBD, upsized its IPO to $289 million – up from $200 million –  in an S-1/A filing early today (Tuesday, Aug. 4, 2026). The California biotech increased the number of shares to 17 million – up […]

Biotechs are heating up the IPO Calendar as August gets under way. Four big biotech IPOs are set to price this week – along with a smaller biotech deal. Altogether, these five deals aim to raise $972 million. The August heat wave is no surprise. U.S. biotech and pharmaceutical sector IPOs produced a weighted average […]